|
WO2016109415A1
(en)
|
2014-12-30 |
2016-07-07 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
|
NZ741324A
(en)
|
2015-09-21 |
2021-09-24 |
Erasmus Univ Medical Center |
Anti-cd47 antibodies and methods of use
|
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
|
CN109689684B
(zh)
*
|
2016-07-06 |
2022-09-23 |
细胞基因公司 |
具有低免疫原性的抗体及其用途
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｃｄ４７併用療法
|
|
BR112019008010A2
(pt)
|
2016-10-20 |
2019-07-09 |
I-Mab |
anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
WO2018081898A1
(en)
*
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
CA3042581A1
(en)
*
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
US20190309066A1
(en)
*
|
2017-03-22 |
2019-10-10 |
Arch Oncology, Inc. |
Combination therapy for the treatment of solid and hematological cancers
|
|
BR112019020185A2
(pt)
*
|
2017-03-27 |
2020-06-02 |
Celgene Corporation |
Métodos e composições para redução da imunogenicidade
|
|
EP3601354A1
(en)
|
2017-03-31 |
2020-02-05 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
MX2019012295A
(es)
|
2017-04-14 |
2020-02-07 |
Tollnine Inc |
Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
|
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
|
CN109096395B
(zh)
*
|
2017-06-20 |
2022-06-24 |
华兰生物工程股份有限公司 |
阻断型cd47纳米抗体及其用途
|
|
SI3642242T1
(sl)
*
|
2017-06-21 |
2024-05-31 |
The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel |
Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti
|
|
AU2018308191B2
(en)
|
2017-07-24 |
2023-12-21 |
Scenic Immunology B.V. |
Treating pathological conditions by direct and indirect targeting of SIRPa - CD47 interaction
|
|
JP7262440B2
(ja)
*
|
2017-08-02 |
2023-04-21 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｃｄ４７抗体及びその使用
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
CN108503708B
(zh)
*
|
2017-09-01 |
2021-07-30 |
北京智仁美博生物科技有限公司 |
抗人cd47抗体及其用途
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
KR102366853B1
(ko)
*
|
2017-11-10 |
2022-02-23 |
아이-맵 바이오파마 유에스 리미티드 |
Cd47 항체 및 사이토카인을 포함하는 융합 단백질
|
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
EP3737401A4
(en)
|
2018-01-12 |
2021-09-15 |
Aurigene Discovery Technologies Limited |
1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
|
|
US20210040224A1
(en)
*
|
2018-03-13 |
2021-02-11 |
Trillium Therapeutics Inc. |
Cd47 blockade therapy with cd38 antibody
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110305212A
(zh)
*
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
WO2019200357A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
CN112566662A
(zh)
*
|
2018-06-15 |
2021-03-26 |
阿库鲁斯生物科学公司 |
针对cd47的阻断抗体及其使用方法
|
|
WO2020009725A1
(en)
*
|
2018-07-05 |
2020-01-09 |
Trican Biotechnology Co., Ltd |
Human anti-cd47 antibodies and uses thereof
|
|
TWI830774B
(zh)
|
2018-08-31 |
2024-02-01 |
大陸商南京聖和藥業股份有限公司 |
抗cd47抗體及其應用
|
|
WO2020072445A1
(en)
*
|
2018-10-01 |
2020-04-09 |
Verastem, Inc. |
Combination therapies
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN113286613A
(zh)
|
2018-10-29 |
2021-08-20 |
Umc乌得勒支控股有限公司 |
IgA介导的通过中性粒细胞的CD47-SIRPα检查点抑制对异常细胞的杀伤
|
|
KR20210096612A
(ko)
*
|
2018-10-29 |
2021-08-05 |
티가티엑스, 인크. |
IgA 항체 구축물을 포함하는 조성물 및 방법
|
|
JP7623279B2
(ja)
|
2018-11-08 |
2025-01-28 |
オーリジーン オンコロジー リミテッド |
小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ
|
|
CN109224079B
(zh)
*
|
2018-11-26 |
2020-08-04 |
中国药科大学 |
Dna甲基转移酶抑制剂与抗cd47抗体联合用于制备抗肿瘤药物的医药用途
|
|
TWI764097B
(zh)
*
|
2019-02-26 |
2022-05-11 |
大陸商信達生物製藥（蘇州）有限公司 |
包含抗ｃｄ４７抗體的製劑及其製備方法和用途
|
|
TW202045550A
(zh)
|
2019-04-05 |
2020-12-16 |
美商西建公司 |
腫瘤選擇性結合cd47之抗體之工程
|
|
CN114072172B
(zh)
*
|
2019-04-18 |
2025-05-13 |
Qlsf生物治疗药物公司 |
靶向人cd47的抗体
|
|
CN114206912B
(zh)
|
2019-06-07 |
2025-02-11 |
Alx肿瘤生物技术公司 |
用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
|
|
CN112206320B
(zh)
*
|
2019-07-12 |
2025-02-25 |
鲁南制药集团股份有限公司 |
一种cd47单克隆抗体冻干粉制剂及其制备工艺
|
|
CN114761041A
(zh)
|
2019-07-16 |
2022-07-15 |
吉利德科学公司 |
Hiv疫苗及其制备和使用方法
|
|
CN112442123B
(zh)
*
|
2019-09-03 |
2022-08-23 |
中山康方生物医药有限公司 |
抗cd47的单克隆抗体及其用途
|
|
CN114555123B
(zh)
|
2019-10-18 |
2024-04-02 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
JP2022553410A
(ja)
*
|
2019-10-23 |
2022-12-22 |
アーチ オンコロジー，インコーポレイテッド |
固形がんおよび血液がんを処置するための併用療法
|
|
JP7520972B2
(ja)
*
|
2019-10-25 |
2024-07-23 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｃｄ４７抗体及びその使用
|
|
KR20220091576A
(ko)
|
2019-10-31 |
2022-06-30 |
포티 세븐, 인코포레이티드 |
혈액암의 항-cd47 및 항-cd20 기반 치료
|
|
WO2021113596A2
(en)
*
|
2019-12-05 |
2021-06-10 |
Sorrento Therapeutics, Inc. |
Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
|
|
WO2021123832A1
(en)
|
2019-12-20 |
2021-06-24 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
LT4081305T
(lt)
|
2019-12-24 |
2024-11-25 |
Carna Biosciences, Inc. |
Diacilglicerolio kinazę moduliuojantys junginiai
|
|
CA3163939A1
(en)
*
|
2020-01-09 |
2021-07-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Application of combination of anti-cd47 antibody and anti-cd20 antibody in preparation of drugs for preventing or treating tumors
|
|
KR20260017503A
(ko)
|
2020-02-14 |
2026-02-05 |
길리애드 사이언시즈, 인코포레이티드 |
Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
|
|
US20230097658A1
(en)
*
|
2020-02-27 |
2023-03-30 |
Fred Hutchinson Cancer Research Center |
Tunable extended release hydrogels
|
|
BR112022017136A2
(pt)
|
2020-02-28 |
2022-10-11 |
Tallac Therapeutics Inc |
Conjugação mediada por transglutaminase
|
|
CN111454359B
(zh)
*
|
2020-03-23 |
2021-06-29 |
倍而达药业（苏州）有限公司 |
Cd47抗体或其免疫活性片段及应用
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
TWI869582B
(zh)
*
|
2020-04-10 |
2025-01-11 |
大陸商和記黃埔醫藥（上海）有限公司 |
抗ｃｄ４７抗體及其用途
|
|
CN119930822B
(zh)
*
|
2020-04-17 |
2025-11-21 |
鲁南制药集团股份有限公司 |
抗cd47单克隆抗体
|
|
MX2022013207A
(es)
*
|
2020-04-23 |
2023-01-24 |
Alpha Beta Holdings Llc |
Metodos y composiciones para el tratamiento de cancer.
|
|
US20230014026A1
(en)
*
|
2020-06-22 |
2023-01-19 |
Morphosys Ag |
Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
WO2022007947A1
(zh)
*
|
2020-07-10 |
2022-01-13 |
信达生物制药(苏州)有限公司 |
抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
|
|
KR20230088370A
(ko)
*
|
2020-09-18 |
2023-06-19 |
아이크노스 사이언스 에스. 아. |
Cd47-cd38 이중특이성 항체
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
US12071481B2
(en)
|
2020-12-23 |
2024-08-27 |
D-10 Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
EP4274853A4
(en)
*
|
2021-01-05 |
2024-12-04 |
National Institute Of Biological Sciences, Beijing |
BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117881698A
(zh)
*
|
2021-06-30 |
2024-04-12 |
创新生物有限公司 |
对cd47具有特异性的人源化抗体及包含其的用于预防或治疗cd47相关疾病的药物组合物
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
KR20240162568A
(ko)
*
|
2022-03-25 |
2024-11-15 |
우시 바이올로직스 아일랜드 리미티드 |
항-her2/항-cd47 분자 및 이의 용도
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN119677546A
(zh)
|
2022-07-12 |
2025-03-21 |
吉利德科学公司 |
Hiv免疫原性多肽和疫苗及其用途
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024121311A1
(en)
*
|
2022-12-07 |
2024-06-13 |
Ichnos Sciences SA |
Cd47/cd38 bispecific antibodies and methods of use to treat leukemia
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4637816A1
(en)
*
|
2022-12-22 |
2025-10-29 |
The Medical College of Wisconsin, Inc. |
Compositions that target cd138 and cd3 and methods of making and using the same
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024309A2
(en)
*
|
2023-07-21 |
2025-01-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of myeloid fcυ receptor depletion
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|